Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
$4.81
-3.6%
$3.82
$1.14
$7.20
$298.88M0.91.16 million shs1.51 million shs
Elutia Inc. stock logo
ELUT
Elutia
$2.04
+0.5%
$1.96
$1.61
$5.12
$83.46M0.8825,923 shs15,286 shs
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
$3.22
-3.9%
$3.28
$1.53
$4.05
$319.99M0.7317,937 shs7,649 shs
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
$8.25
-5.1%
$7.64
$1.73
$11.41
$266.56M3.36784,120 shs826,826 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
-3.61%-6.96%+20.25%+71.17%+22.08%
Elutia Inc. stock logo
ELUT
Elutia
+0.49%+6.25%-5.56%0.00%-44.11%
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
-2.72%+2.74%+8.05%-4.73%+40.61%
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
-5.06%-19.43%+1.73%+115.40%+145.54%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
1.4092 of 5 stars
3.51.00.00.00.60.80.6
Elutia Inc. stock logo
ELUT
Elutia
3.4514 of 5 stars
3.55.00.00.01.93.30.6
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
2.5144 of 5 stars
3.43.00.00.02.11.70.6
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
2.9703 of 5 stars
3.54.00.00.02.03.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
3.00
Buy$9.5097.51% Upside
Elutia Inc. stock logo
ELUT
Elutia
3.00
Buy$8.00292.16% Upside
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
2.80
Moderate Buy$10.40222.98% Upside
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
3.00
Buy$26.83225.25% Upside

Current Analyst Ratings Breakdown

Latest ELUT, SGMT, ALDX, and IVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/24/2025
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$28.00
6/6/2025
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $27.00
5/19/2025
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/9/2025
Elutia Inc. stock logo
ELUT
Elutia
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $8.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
N/AN/AN/AN/A$1.19 per shareN/A
Elutia Inc. stock logo
ELUT
Elutia
$24.38M3.44N/AN/A($1.31) per share-1.56
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
$9.95M30.96N/AN/A($1.21) per share-2.66
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
$2M126.51N/AN/A$5.08 per share1.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
-$55.85M-$0.97N/AN/AN/AN/A-72.58%-52.32%8/7/2025 (Estimated)
Elutia Inc. stock logo
ELUT
Elutia
-$53.95M-$1.93N/AN/AN/A-168.23%N/A-96.70%8/6/2025 (Estimated)
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
-$199.34MN/A0.00N/AN/AN/AN/AN/A9/25/2025 (Estimated)
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
-$45.57M-$1.76N/AN/AN/AN/A-35.21%-34.09%8/13/2025 (Estimated)

Latest ELUT, SGMT, ALDX, and IVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
-$0.57N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
-$0.24N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
-$0.25-$0.17+$0.08-$0.17($0.80) millionN/A
5/8/2025Q1 2025
Elutia Inc. stock logo
ELUT
Elutia
-$0.20-$0.21-$0.01-$0.21$6.65 million$6.03 million
5/8/2025Q1 2025
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
-$0.79-$0.56+$0.23-$0.56N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
N/AN/AN/AN/AN/A
Elutia Inc. stock logo
ELUT
Elutia
N/AN/AN/AN/AN/A
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
N/AN/AN/AN/AN/A
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
0.24
6.49
6.49
Elutia Inc. stock logo
ELUT
Elutia
N/A
0.81
0.70
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
N/A
0.92
0.92
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
N/A
20.34
20.34

Institutional Ownership

CompanyInstitutional Ownership
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
59.71%
Elutia Inc. stock logo
ELUT
Elutia
74.03%
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
19.06%
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
87.86%

Insider Ownership

CompanyInsider Ownership
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
9.60%
Elutia Inc. stock logo
ELUT
Elutia
27.60%
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
32.00%
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
14.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
1059.90 million54.15 millionOptionable
Elutia Inc. stock logo
ELUT
Elutia
18041.12 million29.77 millionNot Optionable
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
10095.66 million65.05 millionNot Optionable
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
830.67 million26.17 millionOptionable

Recent News About These Companies

Analysts Set Sagimet Biosciences Inc. (NASDAQ:SGMT) PT at $26.83
SGMT Sagimet Biosciences Inc. - Seeking Alpha
Sagimet Biosciences Inc. (SGMT) - Yahoo Finance
Sagimet Biosciences Inc.
Sagimet Biosciences Analyst Ratings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aldeyra Therapeutics stock logo

Aldeyra Therapeutics NASDAQ:ALDX

$4.81 -0.18 (-3.61%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$4.87 +0.06 (+1.25%)
As of 08/1/2025 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Elutia stock logo

Elutia NASDAQ:ELUT

$2.04 +0.01 (+0.49%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.04 0.00 (0.00%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Inventiva stock logo

Inventiva NASDAQ:IVA

$3.28 -0.07 (-2.09%)
As of 08/1/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Sagimet Biosciences stock logo

Sagimet Biosciences NASDAQ:SGMT

$8.25 -0.44 (-5.06%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$8.39 +0.14 (+1.68%)
As of 08/1/2025 05:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.